Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $28.9K | $134K | $133K | $55.2K | — | — |
| Revenue growth | — | 363.7% | -1.0% | -58.4% | — | — |
| Operating income | -$3.48M | -$13.8M | -$17.8M | -$22.3M | -$20.4M | -$18.7M |
| Operating margin | -12047.5% | -10323.6% | -13402.5% | -40328.3% | — | — |
| Net income | -$3.58M | -$13.9M | -$17.6M | -$22.3M | -$20.4M | -$20.2M |
| Net margin | -12387.7% | -10371.7% | -13262.0% | -40354.3% | — | — |
| EPS (diluted) | -$1.33 | -$1.37 | -$1.48 | -$1.71 | -$0.89 | -$0.61 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.24M | -$12.4M | -$14.7M | -$18.9M | -$18.9M | -$18.5M |
| Capital expenditures | $20.8K | $94.2K | $119K | $15.4K | $22.5K | — |
| Free cash flow | -$3.26M | -$12.5M | -$14.8M | -$18.9M | -$18.9M | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.49M | $36.9M | $7.31M | $11.8M | $10.4M | $20.8M |
| Total assets | $9.60M | $39.0M | $24.1M | $18.6M | $12.1M | $22.8M |
| Total liabilities | $3.40M | $4.17M | $5.22M | $6.03M | $4.78M | $4.25M |
| Long-term debt | $716K | $590K | $495K | $449K | $328K | $300K |
| Shareholders' equity | $6.20M | $34.8M | $18.9M | $12.6M | $7.34M | $18.6M |
| Retained earnings | -$3.46M | -$7.03M | -$20.9M | -$38.5M | -$60.8M | -$81.2M |
| Shares (wtd avg diluted) | 2.68M | 10.2M | 11.9M | 13.0M | 22.9M | 33.0M |
Every figure is extracted from Gain Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.